Seminario web
Thinking like a regulator: De-risking first-cycle submission review
Regulatory expectations for “submission readiness” have shifted, with agencies increasingly assessing whether your entire development program holds together scientifically, strategically, and operationally. Because submission readiness within organizations is typically structured by discipline, these cross-functional issues can stay buried until late in the cycle. Join our webinar to learn how hidden risks in submission readiness can cause delays, review questions, new studies, and significant impacts on patient access, revenue, approvals, competitiveness, and investor confidence.
Key highlights
- Areas where cross-functional risks commonly occur, such as a clinical program that supports a broader patient population than the eventual label allows, unresolved integration-site or long-term safety risks, or inspection-readiness and administrative gaps
- How to build a cohesive benefit-risk and labeling narrative across modules
- Where to look for common CMC/quality triggers that drive major review questions
- Ways to strengthen endpoint and evidence strategy, including fit-for-purpose real-world evidence (RWE)
- How statistical innovation, data analytics, and predictive AI can help detect inconsistencies earlier and help prioritize risks
- When an independent cross-functional “second look” can strengthen submission readiness prior to agency review
